Title: Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort - PubMed URL Source: https://pubmed.ncbi.nlm.nih.gov/42203321/ Markdown Content: Observational Study Actions . 2026 Jun;46(6):3243-3255. doi: 10.21873/anticanres.18194. [Kelly Victory](https://pubmed.ncbi.nlm.nih.gov/?term=Victory+K&cauthor_id=42203321)[2](https://pubmed.ncbi.nlm.nih.gov/42203321/#full-view-affiliation-2 "The Wellness Company, Boca Raton, FL, U.S.A."),[James A Thorp](https://pubmed.ncbi.nlm.nih.gov/?term=Thorp+JA&cauthor_id=42203321)[2](https://pubmed.ncbi.nlm.nih.gov/42203321/#full-view-affiliation-2 "The Wellness Company, Boca Raton, FL, U.S.A."),[Drew Pinsky](https://pubmed.ncbi.nlm.nih.gov/?term=Pinsky+D&cauthor_id=42203321)[2](https://pubmed.ncbi.nlm.nih.gov/42203321/#full-view-affiliation-2 "The Wellness Company, Boca Raton, FL, U.S.A."),[Alejandro Diaz-Villalobos](https://pubmed.ncbi.nlm.nih.gov/?term=Diaz-Villalobos+A&cauthor_id=42203321)[2](https://pubmed.ncbi.nlm.nih.gov/42203321/#full-view-affiliation-2 "The Wellness Company, Boca Raton, FL, U.S.A."),[Peter Gillooly](https://pubmed.ncbi.nlm.nih.gov/?term=Gillooly+P&cauthor_id=42203321)[2](https://pubmed.ncbi.nlm.nih.gov/42203321/#full-view-affiliation-2 "The Wellness Company, Boca Raton, FL, U.S.A."),[Foster Coulson](https://pubmed.ncbi.nlm.nih.gov/?term=Coulson+F&cauthor_id=42203321)[2](https://pubmed.ncbi.nlm.nih.gov/42203321/#full-view-affiliation-2 "The Wellness Company, Boca Raton, FL, U.S.A."),[Melissa Annazone](https://pubmed.ncbi.nlm.nih.gov/?term=Annazone+M&cauthor_id=42203321)[2](https://pubmed.ncbi.nlm.nih.gov/42203321/#full-view-affiliation-2 "The Wellness Company, Boca Raton, FL, U.S.A."),[Chloe Radesi](https://pubmed.ncbi.nlm.nih.gov/?term=Radesi+C&cauthor_id=42203321)[2](https://pubmed.ncbi.nlm.nih.gov/42203321/#full-view-affiliation-2 "The Wellness Company, Boca Raton, FL, U.S.A."),[Jessica Brooks](https://pubmed.ncbi.nlm.nih.gov/?term=Brooks+J&cauthor_id=42203321)[2](https://pubmed.ncbi.nlm.nih.gov/42203321/#full-view-affiliation-2 "The Wellness Company, Boca Raton, FL, U.S.A."),[Peter A McCULLOUGH](https://pubmed.ncbi.nlm.nih.gov/?term=McCULLOUGH+PA&cauthor_id=42203321)[3](https://pubmed.ncbi.nlm.nih.gov/42203321/#full-view-affiliation-3 "Department of Epidemiology, McCullough Foundation, Dallas, TX, U.S.A.")[2](https://pubmed.ncbi.nlm.nih.gov/42203321/#full-view-affiliation-2 "The Wellness Company, Boca Raton, FL, U.S.A."),[Harvey Risch](https://pubmed.ncbi.nlm.nih.gov/?term=Risch+H&cauthor_id=42203321)[2](https://pubmed.ncbi.nlm.nih.gov/42203321/#full-view-affiliation-2 "The Wellness Company, Boca Raton, FL, U.S.A.")[4](https://pubmed.ncbi.nlm.nih.gov/42203321/#full-view-affiliation-4 "Department of Epidemiology and Public Health, Yale School of Public Health, New Haven, CT, U.S.A.") Affiliations * PMID: **42203321** * DOI: [10.21873/anticanres.18194](https://doi.org/10.21873/anticanres.18194) Observational Study ## Real-world Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort Nicolas Hulscher et al. Anticancer Res.2026 Jun. ## Expression of concern in * [Expression of Concern.](https://pubmed.ncbi.nlm.nih.gov/42300708/) [No authors listed][No authors listed]Anticancer Res. 2026 Jun 9;46(6):e3243. doi: 10.21873/anticanres.18276.Anticancer Res. 2026.PMID: 42300708 ## Abstract **Background/aim:** Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole demonstrate multi-target anticancer activity in preclinical models. This study evaluates real-world patient-reported outcomes, safety, and adherence in patients with cancer using this combination. **Patients and methods:** We analyzed a prospective observational cohort of 197 patients with cancer prescribed ivermectin and mebendazole off-label _via_ a U.S. telemedicine platform. Participants received compounded capsules (25 mg ivermectin, 250 mg mebendazole). Data were collected through standardized digital surveys at baseline and 6-month follow-up. A total of 122 participants (61.9%) completed follow-up. Primary outcomes included self-reported cancer status, adherence, and adverse events. Confidence intervals were calculated using the Wilson method, with dose-stratified analyses using Chi-square tests. **Results:** The cohort had a mean age of 67 years with balanced sex distribution and diverse malignancies, most commonly prostate (27.9%) and breast (18.3%). Median time since diagnosis was 1.2 years, with 37.1% reporting active progression at baseline. At six months, adherence was high, with 86.9% completing the initial prescription and 66.4% remaining on therapy. The Clinical Benefit Ratio (CBR) was 84.4% (95% confidence interval=77.0-89.8%). At follow-up, 48.4% of participants reported tumor regression or no evidence of disease (32.8% NED; 15.6% regression), while 36.1% reported stable disease and 15.6% reported progression. Side effects, reported by 25.4%, were dose-dependent and predominantly mild and primarily gastrointestinal, with 93.6% continuing therapy after adjustment. Concurrent therapies reported included chemotherapy (27.9%), radiation (21.3%), surgery (19.7%), supplements (49.2%), and dietary modification (37.7%). **Conclusion:** In this prospective real-world cohort of patients with cancer, ivermectin and mebendazole were associated with high rates of self-reported clinical benefit and favorable tolerability. These findings are hypothesis-generating and support the need for randomized controlled trials. **Keywords:** Ivermectin; Mebendazole; clinical outcomes; drug repurposing; oncology. Copyright © 2026 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. [PubMed Disclaimer](https://pubmed.ncbi.nlm.nih.gov/disclaimer/) ## Similar articles * [Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.](https://pubmed.ncbi.nlm.nih.gov/36321557/) Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.Crider K, et al.Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.Cochrane Database Syst Rev. 2022.PMID: 36321557 Free PMC article.Updated. * [Anthelmintic drugs for treating ascariasis.](https://pubmed.ncbi.nlm.nih.gov/32289194/) Conterno LO, Turchi MD, Corrêa I, Monteiro de Barros Almeida RA.Conterno LO, et al.Cochrane Database Syst Rev. 2020 Apr 14;4(4):CD010599. doi: 10.1002/14651858.CD010599.pub2.Cochrane Database Syst Rev. 2020.PMID: 32289194 Free PMC article. * [Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.](https://pubmed.ncbi.nlm.nih.gov/33234158/) Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, Campias C, Chaparro Campias E, Achinelli F, Guglielmone HA, Ojeda J, Medina F, Farizano Salazar D, Andino G, Ruiz Diaz NE, Kawerin P, Meza E, Dellamea S, Aquino A, Flores V, Martemucci CN, Vernengo MM, Martinez SM, Segovia JE, Aguirre MG.Vallejos J, et al.Trials. 2020 Nov 24;21(1):965. doi: 10.1186/s13063-020-04813-1.Trials. 2020.PMID: 33234158 Free PMC article. * [Overview of the epidemiology methods and applications: strengths and limitations of observational study designs.](https://pubmed.ncbi.nlm.nih.gov/21132580/) Colditz GA.Colditz GA.Crit Rev Food Sci Nutr. 2010;50 Suppl 1(s1):10-2. doi: 10.1080/10408398.2010.526838.Crit Rev Food Sci Nutr. 2010.PMID: 21132580 Free PMC article. ## Publication types * Actions ## MeSH terms * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions * Actions ## Substances * Actions * Actions * Actions ## LinkOut - more resources * ### Full Text Sources * [HighWire](http://ar.iiarjournals.org/lookup/pmidlookup?view=long&pmid=42203321) * ### Medical * [MedlinePlus Health Information](https://medlineplus.gov/cancer.html) * ### Miscellaneous * [NCI CPTAC Assay Portal](https://assays.cancer.gov/CPTAC-329)